Symbols / AVIR
AVIR Chart
About
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 358.60M |
| Enterprise Value | 35.03M | Income | -147.02M | Sales | — |
| Book/sh | 4.04 | Cash/sh | 4.21 | Dividend Yield | — |
| Payout | 0.00% | Employees | 56 | IPO | — |
| P/E | — | Forward P/E | -2.63 | PEG | — |
| P/S | — | P/B | 1.14 | P/C | — |
| EV/EBITDA | -0.22 | EV/Sales | — | Quick Ratio | 16.32 |
| Current Ratio | 16.66 | Debt/Eq | 0.33 | LT Debt/Eq | — |
| EPS (ttm) | -1.77 | EPS next Y | -1.75 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-05 | ROA | -23.86% |
| ROE | -37.98% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 78.13M |
| Shs Float | 57.96M | Short Float | 12.63% | Short Ratio | 15.83 |
| Short Interest | — | 52W High | 4.80 | 52W Low | 2.46 |
| Beta | 0.23 | Avg Volume | 444.16K | Volume | 14.47K |
| Target Price | $7.67 | Recom | None | Prev Close | $4.65 |
| Price | $4.59 | Change | -1.29% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$7.67
Mean price target
2. Current target
$4.59
Latest analyst target
3. DCF / Fair value
$-17.61
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.59
Low
$6.00
High
$11.00
Mean
$7.67
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-11 | main | Morgan Stanley | Equal-Weight → Equal-Weight | $6 |
| 2024-08-13 | up | Morgan Stanley | Underweight → Equal-Weight | $7 |
| 2023-08-10 | down | JP Morgan | Neutral → Underweight | — |
| 2023-03-16 | main | JP Morgan | — → Neutral | $8 |
| 2023-01-27 | main | SVB Leerink | — → Market Perform | $6 |
| 2023-01-24 | main | Morgan Stanley | — → Underweight | $4 |
| 2022-08-15 | main | Morgan Stanley | — → Underweight | $7 |
| 2022-03-02 | main | JP Morgan | — → Neutral | $8 |
| 2022-03-01 | main | SVB Leerink | — → Market Perform | $9 |
| 2022-02-16 | main | SVB Leerink | — → Market Perform | $10 |
| 2022-01-06 | down | Morgan Stanley | Equal-Weight → Underweight | $7 |
| 2021-11-18 | down | SVB Leerink | Outperform → Market Perform | $11 |
| 2021-10-20 | main | SVB Leerink | — → Outperform | $20 |
| 2021-10-20 | down | JP Morgan | Overweight → Neutral | $16 |
| 2021-10-05 | down | Morgan Stanley | Overweight → Equal-Weight | $55 |
| 2021-09-09 | init | SVB Leerink | — → Outperform | $60 |
| 2021-08-18 | main | Morgan Stanley | — → Overweight | $37 |
| 2021-06-03 | main | Morgan Stanley | — → Overweight | $35 |
| 2021-04-06 | main | Morgan Stanley | — → Overweight | $82 |
| 2021-01-29 | main | JP Morgan | — → Overweight | $66 |
- No approved hepatitis E drugs: experimental pill shows powerful lab results - Stock Titan ue, 24 Feb 2026 12
- Bullish Atea Pharmaceuticals Insiders Loaded Up On US$5.40m Of Stock - Yahoo Finance ue, 13 Jan 2026 08
- Insiders Enjoy US$723k Return After Buying Atea Pharmaceuticals Stock - simplywall.st Fri, 19 Sep 2025 07
- New hepatitis C and E treatments move toward key human clinical trials in 2026 - Stock Titan hu, 08 Jan 2026 08
- Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha ue, 23 Dec 2025 08
- symbol__ Stock Quote Price and Forecast - CNN ue, 26 Mar 2024 12
- Earnings call transcript: Atea Pharmaceuticals Q3 2025 sees EPS miss - Investing.com Wed, 12 Nov 2025 08
- Is AVIR’s ROE strong enough - 2025 Macro Impact & Real-Time Chart Breakout Alerts - mfd.ru Fri, 20 Feb 2026 06
- Here's Why We're Not At All Concerned With Atea Pharmaceuticals' (NASDAQ:AVIR) Cash Burn Situation - Yahoo Finance ue, 17 Jun 2025 07
- Roche Pulls Plug On Atea's Covid Pill After Pfizer Lobs It To FDA - Investor's Business Daily ue, 16 Nov 2021 08
- Discovering Opportunities: Penny Stocks To Consider In October 2025 - simplywall.st hu, 09 Oct 2025 07
- Atea Pharmaceuticals Completes Enrollment in C-BEYOND Phase 3 Trial for HCV Treatment, Anticipates Topline Results in Mid-2026 | AVIR Stock News - Quiver Quantitative Mon, 22 Dec 2025 08
- Is Atea Pharma Moving BEYOND The Virus And FORWARD To Breakthroughs? - RTTNews ue, 23 Dec 2025 08
- Atea Pharmaceuticals, Inc. (AVIR): A Bull Case Theory - Yahoo Finance Fri, 21 Mar 2025 07
- Many Biotechs Are Worth More Dead Than Alive - Barron's Mon, 05 Jun 2023 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 572983 | 372000.0 | — | Conversion of Exercise of derivative security at price 1.24 per share. | SOMMADOSSI JEAN-PIERRE | Chief Executive Officer | — | 2026-02-03 00:00:00 | D |
| 1 | 54866 | nan | — | — | CORCORAN ANDREA J | Officer | — | 2026-01-30 00:00:00 | D |
| 2 | 41333 | nan | — | — | FOSTER WAYNE CPA | Officer | — | 2026-01-30 00:00:00 | D |
| 3 | 51283 | nan | — | — | HORGA MARIA ARANTXA | Officer | — | 2026-01-30 00:00:00 | D |
| 4 | 58050 | nan | — | — | HAMMOND JANET MJ | Officer | — | 2026-01-30 00:00:00 | D |
| 5 | 42083 | nan | — | — | VAVRICKA JOHN | Officer | — | 2026-01-30 00:00:00 | D |
| 6 | 29600 | nan | — | — | DUNCAN BARBARA GAYLE | Director | — | 2025-06-20 00:00:00 | D |
| 7 | 29600 | nan | — | — | BERGER FRANKLIN MILAN | Director | — | 2025-06-20 00:00:00 | D |
| 8 | 29600 | nan | — | — | POLSKY BRUCE | Director | — | 2025-06-20 00:00:00 | D |
| 9 | 29600 | nan | — | — | LUCIDI BRUNO | Director | — | 2025-06-20 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.03 | 0.12 |
| NormalizedEBITDA | -192.53M | -163.75M | -130.39M | 138.41M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -168.38M | -135.96M | -115.91M | 121.19M |
| ReconciledDepreciation | 416.00K | 416.00K | 260.00K | 29.00K |
| EBITDA | -192.53M | -163.75M | -130.39M | 138.41M |
| EBIT | -192.95M | -164.16M | -130.65M | 138.38M |
| NetInterestIncome | 25.49M | 29.22M | 11.15M | 213.00K |
| InterestIncome | 25.49M | 29.22M | 11.15M | 213.00K |
| NormalizedIncome | -168.38M | -135.96M | -115.91M | 121.19M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -168.38M | -135.96M | -115.91M | 121.19M |
| TotalExpenses | 192.95M | 164.16M | 130.65M | 212.99M |
| TotalOperatingIncomeAsReported | -192.95M | -164.16M | -130.65M | 138.38M |
| DilutedAverageShares | 84.26M | 83.39M | 83.25M | 88.25M |
| BasicAverageShares | 84.26M | 83.39M | 83.25M | 82.82M |
| DilutedEPS | -2.00 | -1.63 | -1.39 | 1.37 |
| BasicEPS | -2.00 | -1.63 | -1.39 | 1.46 |
| DilutedNIAvailtoComStockholders | -168.38M | -135.96M | -115.91M | 121.19M |
| NetIncomeCommonStockholders | -168.38M | -135.96M | -115.91M | 121.19M |
| NetIncome | -168.38M | -135.96M | -115.91M | 121.19M |
| NetIncomeIncludingNoncontrollingInterests | -168.38M | -135.96M | -115.91M | 121.19M |
| NetIncomeContinuousOperations | -168.38M | -135.96M | -115.91M | 121.19M |
| TaxProvision | 925.00K | 1.02M | -3.59M | 17.40M |
| PretaxIncome | -167.46M | -134.94M | -119.50M | 138.59M |
| NetNonOperatingInterestIncomeExpense | 25.49M | 29.22M | 11.15M | 213.00K |
| InterestIncomeNonOperating | 25.49M | 29.22M | 11.15M | 213.00K |
| OperatingIncome | -192.95M | -164.16M | -130.65M | 138.38M |
| OperatingExpense | 192.95M | 164.16M | 130.65M | 212.99M |
| ResearchAndDevelopment | 144.10M | 114.24M | 81.94M | 167.21M |
| SellingGeneralAndAdministration | 48.85M | 49.92M | 48.71M | 45.78M |
| GeneralAndAdministrativeExpense | 48.85M | 49.92M | 48.71M | 45.78M |
| OtherGandA | 48.85M | 49.92M | 48.71M | 45.78M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 351.37M |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 351.37M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 84.46M | 83.44M | 83.29M | 83.10M |
| ShareIssued | 84.46M | 83.44M | 83.29M | 83.10M |
| TotalDebt | 1.64M | 2.40M | 3.12M | 197.00K |
| TangibleBookValue | 438.87M | 555.19M | 640.57M | 710.08M |
| InvestedCapital | 438.87M | 555.19M | 640.57M | 710.08M |
| WorkingCapital | 443.75M | 558.08M | 642.44M | 715.52M |
| NetTangibleAssets | 438.87M | 555.19M | 640.57M | 710.08M |
| CapitalLeaseObligations | 1.64M | 2.40M | 3.12M | 197.00K |
| CommonStockEquity | 438.87M | 555.19M | 640.57M | 710.08M |
| TotalCapitalization | 438.87M | 555.19M | 640.57M | 710.08M |
| TotalEquityGrossMinorityInterest | 438.87M | 555.19M | 640.57M | 710.08M |
| StockholdersEquity | 438.87M | 555.19M | 640.57M | 710.08M |
| GainsLossesNotAffectingRetainedEarnings | 233.00K | 207.00K | -684.00K | 0.00 |
| OtherEquityAdjustments | 233.00K | 207.00K | -684.00K | |
| RetainedEarnings | -364.22M | -195.84M | -59.88M | 56.03M |
| AdditionalPaidInCapital | 802.77M | 750.74M | 701.05M | 653.96M |
| CapitalStock | 84.00K | 83.00K | 83.00K | 83.00K |
| CommonStock | 84.00K | 83.00K | 83.00K | 83.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 25.80M | 39.78M | 26.14M | 62.81M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 7.20M | 7.40M | 7.66M | 5.93M |
| OtherNonCurrentLiabilities | 5.93M | |||
| TradeandOtherPayablesNonCurrent | 6.36M | 5.76M | 5.25M | 5.93M |
| LongTermDebtAndCapitalLeaseObligation | 842.00K | 1.64M | 2.40M | 0.00 |
| LongTermCapitalLeaseObligation | 842.00K | 1.64M | 2.40M | 0.00 |
| CurrentLiabilities | 18.60M | 32.38M | 18.48M | 56.88M |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 800.00K | 760.00K | 721.00K | 197.00K |
| CurrentCapitalLeaseObligation | 800.00K | 760.00K | 721.00K | 197.00K |
| PayablesAndAccruedExpenses | 17.80M | 31.62M | 17.76M | 56.69M |
| CurrentAccruedExpenses | 13.35M | 27.36M | 15.11M | 49.58M |
| Payables | 4.46M | 4.25M | 2.65M | 7.11M |
| TotalTaxPayable | 0.00 | 99.00K | 2.57M | |
| IncomeTaxPayable | 0.00 | 99.00K | 2.57M | |
| AccountsPayable | 4.46M | 4.25M | 2.55M | 4.53M |
| TotalAssets | 464.67M | 594.97M | 666.71M | 772.89M |
| TotalNonCurrentAssets | 2.31M | 4.51M | 5.79M | 489.00K |
| OtherNonCurrentAssets | 197.00K | 1.40M | 1.69M | 305.00K |
| NonCurrentPrepaidAssets | 1.49M | 0.00 | ||
| NetPPE | 2.12M | 3.12M | 4.09M | 184.00K |
| AccumulatedDepreciation | -1.10M | -689.00K | -273.00K | -161.00K |
| GrossPPE | 3.22M | 3.81M | 4.37M | 345.00K |
| Leases | 1.48M | 1.48M | 1.48M | 129.00K |
| OtherProperties | 1.25M | 1.83M | 2.39M | 166.00K |
| MachineryFurnitureEquipment | 498.00K | 498.00K | 498.00K | 50.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 462.36M | 590.46M | 660.92M | 772.40M |
| OtherCurrentAssets | 7.63M | 12.35M | 14.21M | 8.03M |
| PrepaidAssets | 8.03M | |||
| Receivables | 0.00 | |||
| CashCashEquivalentsAndShortTermInvestments | 454.72M | 578.11M | 646.71M | 764.38M |
| OtherShortTermInvestments | 390.02M | 434.28M | 458.25M | 0.00 |
| CashAndCashEquivalents | 64.70M | 143.82M | 188.46M | 764.38M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -135.50M | -85.39M | -122.92M | -87.01M |
| IssuanceOfCapitalStock | 230.00K | 1.47M | ||
| CapitalExpenditure | -1.94M | -4.00K | ||
| EndCashPosition | 64.70M | 143.82M | 188.66M | 764.68M |
| BeginningCashPosition | 143.82M | 188.66M | 764.68M | 850.22M |
| ChangesInCash | -79.13M | -44.84M | -576.02M | -85.54M |
| FinancingCashFlow | 267.00K | 257.00K | 370.00K | 1.47M |
| CashFlowFromContinuingFinancingActivities | 267.00K | 257.00K | 370.00K | 1.47M |
| ProceedsFromStockOptionExercised | 267.00K | 257.00K | 370.00K | 0.00 |
| NetPreferredStockIssuance | 0.00 | 0.00 | ||
| PreferredStockIssuance | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 230.00K | 1.47M | ||
| CommonStockIssuance | 230.00K | 1.47M | ||
| InvestingCashFlow | 56.10M | 40.30M | -455.41M | -4.00K |
| CashFlowFromContinuingInvestingActivities | 56.10M | 40.30M | -455.41M | -4.00K |
| NetInvestmentPurchaseAndSale | 56.10M | 40.30M | -453.47M | 0.00 |
| SaleOfInvestment | 517.28M | 602.66M | 91.89M | 0.00 |
| PurchaseOfInvestment | -461.18M | -562.36M | -545.35M | 0.00 |
| NetPPEPurchaseAndSale | 0.00 | -1.94M | -4.00K | |
| PurchaseOfPPE | 0.00 | -1.94M | -4.00K | |
| OperatingCashFlow | -135.50M | -85.39M | -120.98M | -87.00M |
| CashFlowFromContinuingOperatingActivities | -135.50M | -85.39M | -120.98M | -87.00M |
| ChangeInWorkingCapital | -7.48M | 16.16M | -46.59M | -247.84M |
| ChangeInOtherWorkingCapital | -301.37M | |||
| ChangeInOtherCurrentLiabilities | -175.00K | -161.00K | 765.00K | 0.00 |
| ChangeInOtherCurrentAssets | 0.00 | 98.00K | -1.49M | -161.00K |
| ChangeInPayablesAndAccruedExpense | -13.21M | 14.36M | -39.61M | 54.17M |
| ChangeInAccruedExpense | -13.42M | 12.66M | -37.62M | 43.88M |
| ChangeInPayable | 206.00K | 1.70M | -1.98M | 10.29M |
| ChangeInAccountPayable | 206.00K | 1.70M | -1.98M | 10.29M |
| ChangeInPrepaidAssets | 5.91M | 1.86M | -6.25M | -483.00K |
| ChangeInReceivables | 0.00 | 0.00 | ||
| StockBasedCompensation | 51.77M | 49.43M | 46.72M | 39.62M |
| AmortizationOfSecurities | -11.82M | -15.45M | -5.46M | 0.00 |
| DepreciationAmortizationDepletion | 416.00K | 416.00K | 260.00K | 29.00K |
| DepreciationAndAmortization | 416.00K | 416.00K | 260.00K | 29.00K |
| NetIncomeFromContinuingOperations | -168.38M | -135.96M | -115.91M | 121.19M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for AVIR
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|